Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SGMO Stock Forecast 2025-2026
$0.50
Current Price
$122.48M
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SGMO Price Targets
+1,900.0%
To High Target of $10.00
+300.0%
To Median Target of $2.00
+200.0%
To Low Target of $1.50
SGMO Price Momentum
+11.1%
1 Week Change
-35.9%
1 Month Change
-21.9%
1 Year Change
-51.0%
Year-to-Date Change
-84.3%
From 52W High of $3.18
+66.7%
From 52W Low of $0.30
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Sangamo Therapeutics (SGMO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SGMO and similar high-potential opportunities.
Latest SGMO Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, SGMO has a bullish consensus with a median price target of $2.00 (ranging from $1.50 to $10.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $0.50, the median forecast implies a 300.0% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,900.0% upside. Conversely, the most conservative target is provided by Greg Harrison at B of A Securities, suggesting a 200.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SGMO Analyst Ratings
5
Buy
2
Hold
0
Sell
SGMO Price Target Range
Low
$1.50
Average
$2.00
High
$10.00
Current: $0.50
Latest SGMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SGMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Barclays | Gena Wang | Overweight | Maintains | $5.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Mar 18, 2025 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $2.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Jan 23, 2025 | Truist Securities | Nicole Germino | Buy | Maintains | $5.00 |
| Jan 2, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 31, 2024 | Jefferies | Maury Raycroft | Buy | Maintains | $3.00 |
| Dec 31, 2024 | Wells Fargo | Jim Birchenough | Equal-Weight | Maintains | $2.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Nov 14, 2024 | Barclays | Gena Wang | Overweight | Maintains | $9.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $10.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Oct 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 15, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Sangamo Therapeutics Inc. (SGMO) Competitors
The following stocks are similar to Sangamo Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sangamo Therapeutics Inc. (SGMO) Financial Data
Sangamo Therapeutics Inc. has a market capitalization of $122.48M with a P/E ratio of -1.0x. The company generates $63.76M in trailing twelve-month revenue with a -124.6% profit margin.
Revenue growth is +1,238.3% quarter-over-quarter, while maintaining an operating margin of -460.3% and return on equity of -257.9%.
Valuation Metrics
Market Cap
$122.48M
Enterprise Value
$115.93M
P/E Ratio
-1.0x
PEG Ratio
-2.3x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
+1,238.3%
Gross Margin
N/A
Operating Margin
-460.3%
Net Margin
-124.6%
EPS Growth
+1,238.3%
Financial Health
Cash/Price Ratio
+21.6%
Current Ratio
0.8x
Debt/Equity
507.1x
ROE
-257.9%
ROA
-46.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Sangamo Therapeutics Inc. (SGMO) Business Model
About Sangamo Therapeutics Inc.
What They Do
Biotechnology company focusing on genomic therapies.
Business Model
The company develops proprietary zinc finger DNA-binding proteins (ZFPs) to edit and modulate gene expression, positioning itself as a leader in gene therapy and genome editing. Sangamo generates revenue through collaborations with major pharmaceutical companies and by advancing its pipeline of treatments targeting genetic diseases.
Additional Information
Sangamo's focus areas include hemophilia, beta-thalassemia, Fabry disease, and various neurological conditions. As the biotech industry evolves, the company aims to make significant contributions to precision medicine and address complex genetic anomalies and rare diseases worldwide.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
183
CEO
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Country
United States
IPO Year
2000
Website
www.sangamo.comSangamo Therapeutics Inc. (SGMO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -27.27% and 29.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 12, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) will hold its Q1 2025 earnings conference call on May 12, 2025, at 6:30 PM ET, featuring key company executives and analysts.
Why It Matters
Sangamo's Q1 earnings call indicates upcoming financial performance insights, strategic updates, and potential market movements, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sangamo Therapeutics has postponed its Q1 2025 conference call to later on the same day, according to a Business Wire announcement.
Why It Matters
The delay in Sangamo Therapeutics' conference call could signal potential changes or developments in their financial outlook, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
9 days ago
Quick Summary
Sangamo Therapeutics announced recent business highlights and financial results for Q1 2025. Further details on performance were not specified in the excerpt.
Why It Matters
Sangamo Therapeutics' financial results and business highlights signal its performance and strategic direction, impacting investor sentiment and potential stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sangamo Therapeutics (SGMO) reported a quarterly loss of $0.14 per share, worse than the estimated loss of $0.11, but an improvement from a $0.27 loss per share a year earlier.
Why It Matters
Sangamo's larger-than-expected quarterly loss may signal ongoing financial struggles, impacting investor confidence and potentially affecting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Sangamo Therapeutics has priced an underwritten offering to raise $23.0 million.
Why It Matters
Sangamo Therapeutics' $23 million offering indicates capital raising for growth or operational needs, potentially affecting stock value and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sangamo Therapeutics will hold its first quarter 2025 earnings call, as announced in Richmond, California.
Why It Matters
Sangamo Therapeutics' earnings call may reveal financial performance and future outlook, impacting stock value and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SGMO Stock
What is Sangamo Therapeutics Inc.'s (SGMO) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Sangamo Therapeutics Inc. (SGMO) has a median price target of $2.00. The highest price target is $10.00 and the lowest is $1.50.
Is SGMO stock a good investment in 2025?
According to current analyst ratings, SGMO has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SGMO stock?
Wall Street analysts predict SGMO stock could reach $2.00 in the next 12 months. This represents a 300.0% increase from the current price of $0.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sangamo Therapeutics Inc.'s business model?
The company develops proprietary zinc finger DNA-binding proteins (ZFPs) to edit and modulate gene expression, positioning itself as a leader in gene therapy and genome editing. Sangamo generates revenue through collaborations with major pharmaceutical companies and by advancing its pipeline of treatments targeting genetic diseases.
What is the highest forecasted price for SGMO Sangamo Therapeutics Inc.?
The highest price target for SGMO is $10.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,900.0% increase from the current price of $0.50.
What is the lowest forecasted price for SGMO Sangamo Therapeutics Inc.?
The lowest price target for SGMO is $1.50 from Greg Harrison at B of A Securities, which represents a 200.0% increase from the current price of $0.50.
What is the overall SGMO consensus from analysts for Sangamo Therapeutics Inc.?
The overall analyst consensus for SGMO is bullish. Out of 11 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are SGMO stock price projections?
Stock price projections, including those for Sangamo Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 4:26 AM UTC